NEW YORK, March  30, 2026  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&amp;D) co-funding agreement with Johnson &amp; Johnson for a total of $500 million in 2026 and

RPRX

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Royalty Pharma Partners with Johnson & Johnson in $500M Research Agreement

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, March  30, 2026  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&amp;amp;D) co-funding agreement with Johnson &amp;amp; Johnson for a total of $500 million in 2026 and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Royalty Pharma plc has entered a $500 million co-funding agreement with Johnson &amp; Johnson for the development of JNJ-4804, an innovative therapy targeting autoimmune diseases. This collaboration aligns with Royalty Pharma&#039;s strategic commitment to the immunology space, potentially enhancing future revenue from royalties as the drug progresses in clinical trials.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Royalty Pharma signs $500M R&amp;D agreement with Johnson &amp; Johnson.</li><li>Funding is for developing JNJ-4804, a new autoimmune disease treatment.</li><li>JNJ-4804 targets IL-23 and TNF pathways for chronic diseases.</li><li>The partnership leverages Royalty Pharma&#039;s immunology investment track record.</li><li>The collaboration highlights growth potential in immune-mediated therapies.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Johnson &amp; Johnson (JNJ)</strong>: Partnership may enhance both companies&#039; market positions in immunology.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under &#039;Corporate Developments&#039; as it highlights key strategic partnerships that can accelerate drug development and potentially unlock considerable value for Royalty Pharma. This collaboration is indicative of shifting trends towards innovative therapies in the biopharmaceutical space.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The $500 million funding may signal future royalty income growth.</li><li>Success in JNJ-4804 trials could boost RPRX&#039;s share price significantly.</li><li>Immunology sector potential can enhance investor interest in RPRX.</li><li>Strong collaboration with J&amp;J may attract more partnerships.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Royalty Pharma to invest $500 million in 2026 and 2027.</li><li>JNJ-4804 targets autoimmune diseases through dual mechanisms.</li><li>Royalty Pharma has a substantial portfolio of over 35 therapies.</li><li>Pablo Legorreta is CEO &amp; Chairman of Royalty Pharma.</li><li>The agreement showcases Royalty Pharma&#039;s strength in immunology.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on RPRX given growth prospects from JNJ-4804 partnership.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="left">NEW YORK, March  30, 2026  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RPRX">RPRX</a>) today announced a research and development (R&amp;D) co-funding agreement with Johnson &amp; Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.</p>  <p>JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases.</p>  <p>"We are delighted to collaborate with Johnson &amp; Johnson on the clinical development of JNJ-4804," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Royalty Pharma has a strong track record of investing in immunology, beginning with early disease-modifying biologics including TNF inhibitors. Johnson &amp; Johnson is a recognized leader in immunology and we believe JNJ-4804 holds substantial promise for patients with chronic immune-mediated diseases. We see this as an exciting opportunity that builds on our commitment to partnering with global biopharma companies."</p>  <p><strong>Advisors</strong></p>  <p>Goodwin Procter LLP acted as legal advisors to Royalty Pharma.</p>  <p><strong>About Royalty Pharma plc</strong></p>  <p>Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, Johnson &amp; Johnson's Tremfya, GSK's Trelegy, Roche's Evrysdi, Servier's Voranigo, Biogen's Tysabri and Spinraza, AbbVie and Johnson &amp; Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, among others, and 19 development-stage product candidates. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=WoPA02iM_Lg6UUhVz43uBOh22AZLrPvcIN4MjuDAotIu3XEgd40-VT-KIpP6P4X7dbDT4fmCl4I41z79JficAZAps8H5ybGP3q5buSs-1BY=" rel="nofollow" target="_blank">www.royaltypharma.com</a>.</p>  <p><strong>Royalty Pharma Forward-Looking Statements</strong></p>  <p>The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities, market growth, and plans for capital deployment. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference Royalty Pharma's reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at <a href="https://www.globenewswire.com/Tracker?data=4GjyC9wLT1QhhzNVk8Ppudy7ZyAmwkYUdiKv8WS1by95dj2tAwBIidPGJZPlGY9qxqywfjjFPphKYCT-Wqc7gQ==" rel="nofollow" target="_blank">www.sec.gov</a>.</p>  <p><strong>Royalty Pharma Investor Relations and Communications</strong></p>  <p>+1 (212) 883-6637<br></br><a href="https://www.globenewswire.com/Tracker?data=qrwFjenoTbUNK6gShJj4FThNZBjE8_sPVXqmLhDXcuMU1k0MU_f0aPI6QW8F0pIO6hCJjqU_FO3Y01ILCffAt92tLunziTno1ZRay9CSqJw=" rel="nofollow" target="_blank">ir@royaltypharma.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4MDQ2OCM3NTA5Mjg0IzUwMDEwNTI2NA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NDA3NDJkZDQtMjkxZS00NzEwLWJmMjAtMWE3MDM1MDIzYWFlLTUwMDEwNTI2NC0yMDI2LTAzLTMwLWVu/tiny/Royalty-Pharma-plc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d605b3b0-7ba0-46e1-a2d4-439ca98694f8"><img src="https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg" border="0" width="150" height="9" alt="Primary Logo"></img></a></p>

Royalty Pharma plc has entered a $500 million co-funding agreement with Johnson & Johnson for the development of JNJ-4804, an innovative therapy targeting autoimmune diseases. This collaboration aligns with Royalty Pharma's strategic commitment to the immunology space, potentially enhancing future revenue from royalties as the drug progresses in clinical trials.

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News